Hear from Heidi Manna, Chief People Officer, on how the Jazz Remix flexible working model is designed to provide a greater level of flexibility to how and where work gets done, helping teams pioneer solutions to transform the lives of patients.

Sam Pearce stepped into the newly created position of Jazz Chief Commercial Officer in August 2024, bringing with her an established track record of effectively scaling commercial operations to achieve transformational growth and accelerate patient access to medicines across geographies. One hundred days in, Sam shares her initial experiences and vision for the future of her role and Jazz.

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare and severe epilepsies which are characterized by seizures and significant developmental delays. Most DEEs begin in early life, often in infancy, with children experiencing frequent and severe seizures, which can be of multiple types. This generates a complex clinical picture in which both developmental abnormalities and severe epilepsy contribute to the functional impairment of these children which continues into adulthood.

In this video, watch Mat Davis, PhD, Vice President, Head of Data Science, Evidence and Value Generation, discuss how we leverage focused and integrated quantitative methods in our R&D process to transform patient lives.

Establishing expert consensus treatment recommendations is imperative to providing more people with consistent care. As a leader in neuroscience, we are committed to empowering those we serve through innovative science and thoughtful real-world evidence.

As a long-time leader in sleep medicine, we have come to understand the importance of providing solutions that address patients’ lives holistically, especially for those living with serious, debilitating rare disorders. Read more about how we’re delivering on this promise and supporting the sleep community at SLEEP 2024, the 38^th annual meeting of the Associated Professional Sleep Societies.